Journal
DRUG DISCOVERY TODAY
Volume 14, Issue 11-12, Pages 541-551Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2009.02.009
Keywords
-
Categories
Ask authors/readers for more resources
New generation vaccines will increasingly comprise highly purified recombinant proteins. Unfortunately, these antigens are often poorly immunogenic. Therefore, adjuvants will be required to enable these proteins to become effective vaccines. Although several novel adjuvants have recently emerged, including formulations comprising more than one adjuvant, the approval of vaccines containing novel adjuvants has been slow, particularly in the US. However, despite significant ongoing concerns, the necessary safety data is now emerging to show that new generation adjuvants can be safely used in diverse human populations. In combination with data showing the positive contributions of the adjuvants to the immune response, this safety data should allow several vaccines containing novel adjuvants to obtain licensure within the next few years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available